Company
Who we are
What we do
Investor relations
News & key figures
Investor presentation
Xlife dates
ESG
Projects
Technology Platforms
Biotech and Therapies
Medical Technology
Artificial Intelligence
Contact
DE
Collaborative
Analyst coverage
Institute
Analyst
Target price
Report
Intron Health Research
Dominic Rose
47 CHF
view
Baader Bank
Amandeep Goyal
69.8 CHF
view
Stifel
Daniel Jelovcan
68 CHF
view
News
Press Releases
5.2.24
Xlife Sciences AG Expands Collaboration with Department of Health Abu Dhabi, Partners with Thermo Fisher Scientific and Masdar City
22.12.23
Xlife Sciences AG Achieves Significant Milestone in the Development of Radiodiagnostics for Liver Diseases
20.12.23
Xlife Sciences AG paves the way for the next successful out-licensing and announces cooperation with Quant Biomarkers AG for the development of advanced biomarkers for kidney diseases
Archive
Ad hoc News
29.12.2023
VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline
18.12.2023
Revolutionary AI Algorithm «Prostate.Carcinoma.ai» Achieves EU MDR Class IIa Registration
18.10.2023
Successful exit of portfolio company and major invest in AI and digital health in early cancer detection, valued at CHF 23.3 million
Archive
Downloads
Financial Reports
September 21, 2023
Half-Year Report 2023
April 27, 2023
Valuation Report 2022
April 20, 2023
Annual Report 2022
September 28, 2022
Half-Year Report 2022
May 9, 2022
Valuation Report 2021
April 29, 2022
Annual Report 2021
February 8, 2022
Interim financial statement Q3 2021 (only in german)
August 5, 2021
Semi-Annual Report 2021
Half-year results (only available in German)
May 29, 2020
Annual statement 2020
Sign up for our media releases